Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2008
Business Overview: Merit Medical Systems designs, manufactures, and markets medical devices, primarily for interventional cardiology, radiology, and vascular access. The company reported 27,600,139 shares of common stock outstanding as of May 5, 2008.
Key Financial Metrics
| Metric (in thousands) | Q1 2008 | Q1 2007 |
|---|---|---|
| Net Sales | $53,553 | $51,030 |
| Gross Profit | $21,592 | $18,858 |
| Gross Margin | 40.3% | 37.0% |
| Operating Income | $6,604 | $4,479 |
| Net Income | $4,317 | $2,969 |
| Diluted EPS | $0.15 | $0.10 |
| Cash from Operations | $9,603 | $5,794 |
| Cash and Equivalents (End of Period) | $23,757 | $9,645 |
| Working Capital | $63,276 | $60,194 |
| Total Debt | $0 | $0 |
Note: Working Capital calculated as Total Current Assets ($88,438) minus Total Current Liabilities ($25,162). The company maintained $0 outstanding on its $31 million aggregate lines of credit.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 5% ($2.5 million) year-over-year, driven by a 7% increase in inflation devices, 6% in stand-alone devices, and 11% in catheters. Foreign currency exchange rates (Euro/GBP) contributed a 1.3% increase to sales.
- Margin Expansion: Gross margin improved from 37.0% to 40.3%. Management attributes this to an 18% reduction in manufacturing headcount, lower unit costs from Mexico-based production, automation, and product mix improvements.
- Profitability: Net income rose 45% to $4.3 million. Operating income increased 47% to $6.6 million.
- Expense Management: R&D expenses decreased as a percentage of sales (4.6% to 3.6%) due to headcount reductions in late 2007. SG&A expenses increased slightly as a percentage of sales (23.5% to 24.4%) due to bonuses, legal costs for acquisitions, and amortization of intangibles.
- Acquisitions: In Q1 2008, the company acquired three catheter platforms from Micrus Endovascular Corporation for $3.0 million ($1.5 million cash paid, $1.5 million accrued). This added $2.1 million in goodwill.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management intends to continue developing manufacturing efficiencies and focusing sales efforts on higher-margin products, including new introductions. Two product lines were transferred to a contract manufacturer in Mexico during the quarter.
- Tax Rate: The effective tax rate increased to 36.0% from 35.0%, primarily due to the lapse of the federal R&D tax credit for 2008 and a decrease in permanent tax benefits relative to higher earnings. The company settled two IRS audits, paying an additional $2.2 million, though this had no material impact as liabilities were previously recognized.
- Liquidity: The company generated $9.6 million in operating cash flow. With a current ratio of 3.5 to 1 and no variable rate debt, management believes current liquidity is adequate for foreseeable operations.
- Market Risks:
- Currency: Approximately 13% of revenue is denominated in Euros and GBP. A stronger USD reduces reported revenue. The company uses forward contracts to hedge exposure.
- Regulatory/Competition: Risks include delays in regulatory approvals, product recalls, and competition from new technologies.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and integration costs of the Micrus Endovascular assets acquired in January 2008.
- Manufacturing Efficiency: Confirm the sustained impact of the 18% manufacturing headcount reduction and Mexico outsourcing on future gross margins.
- Tax Position: Monitor the impact of the lapsed R&D tax credit on future effective tax rates and cash tax payments.
- Inventory Levels: Review inventory turnover given the $34.6 million balance and the company's focus on obsolescence reserves ($2.5 million).
- Foreign Exchange Sensitivity: Assess the impact of USD strength on future quarters given the 13% exposure to Euro/GBP revenues.